Announcements Trials

Browse Landscape

Status

Recruiting 3 Completed 2 Withdrawn 1 Unknown 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 83 Carcinoma, Non-Small-Cell Lung 79 Breast Neoplasms 71 Leukemia, Myeloid, Acute 39 Colorectal Neoplasms 37 Recurrence 36 Prostatic Neoplasms 34 Neoplasm Metastasis 30 Multiple Myeloma 28 Lymphoma 26 Pancreatic Neoplasms 25 Melanoma 25 Lymphoma, Non-Hodgkin 24 Lung Neoplasms 24 Leukemia, Lymphocytic, Chronic, B-Cell 23 Ovarian Neoplasms 22 Lymphoma, Follicular 22 Carcinoma, Hepatocellular 22 Carcinoma, Renal Cell 21 Stomach Neoplasms 19 Squamous Cell Carcinoma of Head and Neck 19 Lymphoma, Large B-Cell, Diffuse 19 Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Myelodysplastic Syndromes 18 Leukemia 18 Head and Neck Neoplasms 18 Urinary Bladder Neoplasms 17 Hematologic Neoplasms 14 Carcinoma 13 Uterine Cervical Neoplasms 12

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × INDUSTRY × von Hippel-Lindau Disease × Clear all

NCT06554730 2024-11-29

MK-6482-026

Merck Sharp & Dohme LLC

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡